Dermata Therapeutics, Inc. (DRMA) News

Dermata Therapeutics, Inc. (DRMA): $0.51

-0.14 (-21.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DRMA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 458

in industry

Filter DRMA News Items

DRMA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest DRMA News From Around the Web

Below are the latest news stories about Dermata Therapeutics Inc that investors may wish to consider to help them evaluate DRMA as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | February 10, 2022

Dermata, Innoviva top healthcare gainers; while InfuSystem, Seagen lead losers pack

Gainers: Dermata Therapeutics DRMA +35%. Innoviva (INVA) +11%. Mainz Biomed (MYNZ) +9%. Regional Health Properties RHE +9%. Envista Holdings (NVST) +8%.Losers: InfuSystem

Seeking Alpha | February 10, 2022

Thinking about buying stock in Dermata Therapeutics, Ironnet, Preferred Apartment Communities, Mattel, or Viking Therapeutics?

NEW YORK , Feb. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRMA, IRNT, APTS, MAT, and VKTX. Full story available on Benzinga.com

Benzinga | February 10, 2022

IceCure Medical, Atossa top healthcare gainers; Dermata, Statera among losers

IceCure Medical ICCM +16%. Atossa Therapeutics (ATOS) +15%. Dermata Therapeutics (DRMA) -31%. Statera Biopharma STAB -26%.

Seeking Alpha | February 7, 2022

Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know

Dermata Therapeutics Inc (NASDAQ: DRMA ) has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting for its DMT310 acne program. The Company said it has already planned and budgeted to conduct both studies. The requests come as DMT310 has been used in clinical trials by over 170 patients exhibiting an acceptable safety and tolerability profile. Further, the FDA approved the Company … Full story available on Benzinga.com

Benzinga | February 7, 2022

Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors

SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today announced the appointment of Brittany Bradrick to its Board of Directors and its Audit Committee.

Yahoo | January 13, 2022

Dermata to Present at the H.C. Wainwright BioConnect Conference

SAN DIEGO, CA / ACCESSWIRE / January 5, 2022/ Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman of the Board, President, and Chief Executive Officer, will present a company overview at the H.

Yahoo | January 5, 2022

-$0.25 EPS Expected for Dermata Therapeutics Inc (NASDAQ:DRMA) This Quarter

Wall Street analysts forecast that Dermata Therapeutics Inc (NASDAQ:DRMA) will post earnings per share of ($0.25) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Dermata Therapeutics earnings. The firm is scheduled to issue its next quarterly earnings report on Monday, December 27th. On average, analysts expect that Dermata Therapeutics []

Transcript Daily | December 12, 2021

Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Dermata Therapeutics (DRMA)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Werewolf Therapeutics (HOWL – Research Report) and Dermata Therapeutics (DRMA – Research Report) with bullish sentiments. Werewolf Therapeutics (HOWL) H.C. Wainwright analyst Michael King reiterated a Buy rating on Werewolf Therapeutics today and set a price target of $32.00. The company's shares closed last Wednesday at $14.65. According to TipRanks.

Howard Kim on TipRanks | December 1, 2021

Zacks Investment Research Downgrades Dermata Therapeutics (NASDAQ:DRMA) to Sell

Dermata Therapeutics (NASDAQ:DRMA) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, Dermata Therapeutics Inc. is a privately held biotechnology company. It focused on treatment of medical and aesthetic skin diseases and conditions. The companys product pipeline consist []

Dakota Financial News | November 23, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4942 seconds.